Pharma and Biotech
By Alexander Bueso
Date: Wednesday 06 Sep 2023
(Sharecast News) - Oxford Nanopore Technologies saw its first half loss widen sharply as the company lost legacy Covid testing revenues.
By Alexander Bueso
Date: Monday 17 Jul 2023
(Sharecast News) - Oxford Nanopore guided towards a big increase in first half sales while reiterating its full-year guidance for the same.
By Iain Gilbert
Date: Tuesday 17 Jan 2023
(Sharecast News) - Molecular diagnostics group Oxford Nanopore said on Tuesday that full-year revenues had risen in 2022, driven by growth across all customer groups.
Currency | UK Pounds |
Share Price | 197.10p |
Change Today | -8.50p |
% Change | -4.13 % |
52 Week High | 297.00 |
52 Week Low | 176.60 |
Volume | 505,370 |
Shares Issued | 829.19m |
Market Cap | £1,634.33m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:45 | 51 @ 198.90p |
16:35 | 49,730 @ 197.10p |
16:35 | 914 @ 197.10p |
16:35 | 1,700 @ 197.10p |
16:35 | 1,699 @ 197.10p |
CEO | Gurdial (Gordon) Sanghera |
CFO | Timothy Cowper |
You are here: research